Ancino launches generic Exelon patch

AESCH, Switzerland — Ancino this week launched its rivastigmine patch, a generic version of the Exelon patch. The transdermal treatment is intended for mild to moderate dementia associated with Alzheimer’s disease, and is available in 4.6-mg 24-hour strength, 9.5-mg 24-hour strength and 13.3-mg 24-hour strength.

Acino’s rivastigmine patch will be marketed by Alvogen. This is the first of a series of products Acino plans to launch in the U.S., building on its patch business in Europe